多替阿巴拉米片医保能报销吗？

It is reported that it has not been included in domestic medical insurance and is a drug paid for by patients at their own expense. The price of Suimeike (Dolutea, Inbec) on the market in China is relatively expensive, and most patients cannot afford it. The domestic price of Suimeike (Dolutea, Inbec) is 2880$/month. Patients who cannot afford domestic Suimeike (Dolutea, Inbec) can choose to buy Suimeike (Dolutea, Inbec) which is available in India, and the price is relatively cheap. Inbec, produced by the Indian company Emcure, has a box of 30 tablets and sells for about RMB 1,000. Due to the floating exchange rate, the price cannot be determined. Please consult Medical Travel for specific prices.

On January 22, 2018, GlaxoSmithKline (GSK) announced that its controlled joint venture ViiV Healthcare's single-tablet compound preparation Triumeq (chemical name: dolutegravir), which is used to treat HIV and is based on the new generation integrase inhibitor Triumeq (chemical name: dolutegravir), was officially launched in mainland China. It has the characteristics of high efficacy, good tolerability, high resistance barrier, and few drug interactions. 

It is currently the only three-in-one compound drug containing dolutegravir (DrG), which integrates treatment drugs for different stages of viral infection in the same tablet. Patients only need to take one drug to achieve the effect of combined medication. The drug has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection. One tablet of Suimeike contains three antiviral drugs. One tablet is a complete treatment plan. One tablet a day can achieve the effect of cocktail therapy without food restrictions.